The most read scientific articles in interventional cardiology in March on our website

Below, we share March’s most read scientific abstracts in interventional cardiology at solaci.org. ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable<a href="https://solaci.org/en/2023/04/13/the-most-read-scientific-articles-in-interventional-cardiology-in-march-on-our-website/" title="Read more" >...</a>

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

TriClip: Tricuspid Regurgitation Dedicated Device

Severe tricuspid regurgitation (TR) is difficult to manage and is associated to high morbimortality.  Surgical repair is complex and not free from complications: its mortality rate ranges from 5 to 20% and depends on series, surgeon and center expertise. Edge-to-edge repair with clips has become a valid alternative to treat this disease, but most data<a href="https://solaci.org/en/2023/03/22/triclip-tricuspid-regurgitation-dedicated-device/" title="Read more" >...</a>

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

COAPT: Promising 5-Year Outcomes

Secondary ischemic and non-ischemic mitral valve failure (SMR), produce left ventricle dilation, papillary muscle displacement, and impaired leaflet closure causing regurgitation. This will lead to ventricular function deterioration and bad prognosis.  Edge-to-edge mitral valve repair with MitraClip has been shown safe and effective to treat SMR in the short term, but its evolution at 5<a href="https://solaci.org/en/2023/03/17/coapt-promising-5-year-outcomes/" title="Read more" >...</a>

ACC 2023 | TAVR in Low Risk Patients: 3-Year Outcomes

At present, transcatheter aortic valve replacement (TAVR) has become the gold standard in the US, regardless surgical risk. The current ACC and AHA guidelines recommend that a Heart Team make the decision for 65 to 80-year-old patients with aortic stenosis.  In low risk patients, fast recovery and short term benefits of TAVR should be weighed<a href="https://solaci.org/en/2023/03/08/acc-2023-tavr-in-low-risk-patients-3-year-outcomes/" title="Read more" >...</a>

The most read articles of january in solaci.org

These were the most read articles of interventional cardiology in solaci.org. Real-World Revascularization Strategy for Left Main Coronary Artery: Surgery or PCI? There are many current randomized trials comparing percutaneous coronary intervention (PCI) with myocardial revascularization surgery (MRS) for the treatment of left main coronary artery disease (LMCAD). Real-World Results of Different Devices for TAVR Transcatheter aortic valve replacement (TAVR) keeps<a href="https://solaci.org/en/2023/02/06/the-most-read-articles-of-january-in-solaci-org/" title="Read more" >...</a>

Evolución de pacientes jóvenes con miocardiopatía hipertrófica tratados con ablación septal por alcoholización.

Resistant Obstructive Hypertrophic Cardiomyopathy: Myomectomy or Septal Ablation?

Approximately 70% of hypertrophic cardiomyopathies (HCM) are associated to a left ventricular outflow tract (LVOT) obstruction and mitral valve failure leading to dyspnea and cardiac failure in a high number of patients.  Even though at present there are effective drug treatments combined with pacemaker implantation, surgery (septal myomectomy (SM) continues to be the first choice<a href="https://solaci.org/en/2023/01/25/resistant-obstructive-hypertrophic-cardiomyopathy-myomectomy-or-septal-ablation/" title="Read more" >...</a>

The Most Important Articles of 2022 in Structural Heart Disease

Discover the most read scientific articles on interventional cardiology of 2022 in our website. We Should Treat Significant Stable CAD in Patients Undergoing TAVR Aortic stenosis is associated to significant coronary artery disease (CAD) in nearly 50% of cases. When we decide to treat aortic disease using surgery, it has been established we should also treat<a href="https://solaci.org/en/2023/01/12/the-most-important-articles-of-2022-in-structural-heart-disease/" title="Read more" >...</a>

Is the PASCAL Device Effective against MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy and full medical treatment at maximal tolerated doses has been shown quite effective to treat it. However, its limited in a group of patients that require valve intervention.  At present, the ideal treatment is surgical valve replacement, which is in many cases is not viable because of<a href="https://solaci.org/en/2022/12/30/is-the-pascal-device-effective-against-mitraclip/" title="Read more" >...</a>

Inflamación crónica, enfermedad coronaria y cáncer: distintas caras de una misma moneda

We Should Start Considering Pulmonary Hypertension After TAVR

Pulmonary hypertension is associated with higher mortality after both aortic valve replacement and transcatheter aortic valve replacement (TAVR). This is a dynamic phenomenon, and what happens after TAVR —during the periprocedure— and its impact are yet to be evaluated. Researchers conducted a subanalysis of the Japanese OCEAN TAVI Registry, which included 1872 patients who were divided<a href="https://solaci.org/en/2022/10/25/we-should-start-considering-pulmonary-hypertension-after-tavr/" title="Read more" >...</a>

A Simple Score for Mortality and Cardiac Failure after Edge-to-Edge with MitraClip

Mitral regurgitation (MR) is the most frequent type of valve heart disease, and the COAPT has shown that edge-to-edge with guideline directed medical treatment (GDMT) at maximal tolerated dose (MTD) is superior to medical treatment alone.  However, we did not have a score to predict patient evolution when treated with this strategy. Researchers analyzed the<a href="https://solaci.org/en/2022/10/14/a-simple-score-for-mortality-and-cardiac-failure-after-edge-to-edge-with-mitraclip/" title="Read more" >...</a>

transcatheter mitral valve